Welcome to
On Feet Nation
umair Online
rimeton454 Online
Steve Online
Exenatide, powder for injection, 2 mg, Bydureon
1. Purpose of Application
The major re-submission requested listing of a 2 mg once weekly formulation for the treatment of Type 2 diabetes as:Exenatide acetate powder,Exenatide powder
1) Dual combination therapy with metformin or a sulfonylurea in a patient who meets certain criteria; and
2) Triple combination therapy with metformin and a sulfonylurea in a patient who meets certain criteria.
2. Background
This was the third consideration by the PBAC of the once weekly formulation. Exenatide 5 mcg and 10 mcg (twice daily) have been PBS listed since 1 August 2010.
The Public Summary Document for a submission rejected by the PBAC in July 2011 is available on the PBS website.
At the July 2013 meeting, the PBAC rejected a minor submission for exenatide once weekly injection on the basis of no new data presented to support the claims of comparative effectiveness and safety and unclear cost-offsets.
3. Registration Status
Exenatide 2 mg powder for injection was registered by the TGA on 20 December 2012 for:
The treatment of type 2 diabetes mellitus in combination with metformin; or sulfonylureas; or metformin and a sulfonylurea in patients who have not achieved adequate glycaemic control.
4. Listing Requested and PBAC’s View
The requested listing was unchanged from the previous submission:
Authority required (STREAMLINED)
Dual combination therapy with metformin or a sulfonylurea.
Type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated.
Triple combination therapy with metformin and a sulfonylurea.
Type 2 diabetes, in combination with metformin and a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a dipeptidyl peptidase 4 inhibitor (gliptin), a thiazolidinedione (glitazone) or a glucagon-like peptide-1 despite treatment with maximally tolerated doses of metformin and a sulfonylurea
© 2024 Created by PH the vintage. Powered by
You need to be a member of On Feet Nation to add comments!
Join On Feet Nation